Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 29, 2007 Brian Lawler	Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader.
The Motley Fool April 24, 2007 Brian Lawler	Amgen On Sale? Biotech giant Amgen announces first-quarter financial results. Longer-term investors willing to wait for Amgen's drug pipeline to mature may be getting their chance to own a proven Ferrari at Ford prices.
The Motley Fool July 30, 2007 Brian Lawler	Amgen Adjusting Amgen's second quarter reflects the pain it's feeling with its top drugs. Investors, take note.
The Motley Fool January 25, 2008 Brian Lawler	Amgen: Punched Out or Still Fighting? Amgen manages to pull off a 3.5% increase in revenue for 2007, even with sales of its anemia franchise drugs Aranesp and Epogen down a combined 17% year over year in the fourth quarter.
The Motley Fool January 29, 2007 Brian Lawler	No Amplified Growth for Amgen The drug developer recently released its fourth-quarter financial results. With a $71 share price and trading at roughly a forward multiple of 16 times earnings, the stock is not particularly cheap.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool December 26, 2006 Brian Lawler	2006 in Review: Amgen For investors in shares of Amgen, it hasn't been a good year. The stock has been down more than 7% year to date. Despite this fact, Amgen has had successes on all fronts this year.
The Motley Fool September 6, 2007 Brian Lawler	Amgen's Congressional Helpers Lawmakers push to ease restrictions on anemia compounds from Amgen and Johnson & Johnson. Investors, take note.
The Motley Fool January 7, 2010 Brian Orelli	Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA.
The Motley Fool July 21, 2006 Brian Lawler	Amgen's Little Helpers Sluggish earnings are offset by promising drugs in the pipeline. The bottom line with Amgen is that it is one of the best-run biotechs, period. Investors, take note.
BusinessWeek May 15, 2006 Arlene Weintraub	Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors.
The Motley Fool July 28, 2009 Brian Orelli	Amgen Secures Its Future Earnings and a marketing partnership -- oh my.
The Motley Fool January 26, 2010 Brian Orelli	Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010.
The Motley Fool July 21, 2005 Tom Taulli	Amgen One-Ups Genentech New Medicare regulations look to be harmless, and as a result, Amgen is off to the races. Still, investing in biotech is always dicey.
The Motley Fool May 14, 2007 Mike Havrilla	A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs.
The Motley Fool January 28, 2008 Brian Lawler	A Wing and a Prayer for Amgen Amgen announces data from its top pipeline drug candidate. Investors, take note.
The Motley Fool July 30, 2010 Brian Orelli	On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually.
The Motley Fool June 2, 2010 Brian Orelli	Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market.
BusinessWeek June 4, 2007 Gene G. Marcial	Amgen Believers There has been a deluge of bad news at biotech Amgen, whose stock has tumbled.
The Motley Fool May 29, 2007 Brian Lawler	Amgen Is Vexed The European Union medical authority says no to Amgen's cancer compound. Investors, take note.
The Motley Fool October 26, 2010 Brian Orelli	Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth.
The Motley Fool September 10, 2007 Brian Lawler	Get a Glimpse of Amgen's Future Investors will want to pay attention to an FDA advisory panel meeting discussing new labeling recommendations for Amgen's anemia medications. The two drugs represented 44% of the pharmaceutical company's second-quarter revenue.
The Motley Fool March 25, 2010 Brian Orelli	More Than $5.3 Billion in Revenue Under Attack After dealing with the FDA, Amgen and J&J now have to deal with the Centers for Medicare & Medicaid Services.
The Motley Fool October 22, 2009 Brian Orelli	Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia.
The Motley Fool January 27, 2009 Brian Orelli	Amgen's Anemic Again 2009 won't be stellar, but the future looks better.
The Motley Fool December 10, 2007 Brian Lawler	Amgen Under Review The FDA plans another debate about an Amgen top drug.
The Motley Fool April 21, 2011 Luke Timmerman	Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis.
The Motley Fool July 12, 2004 Ben McClure	Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good.
The Motley Fool October 25, 2011 Brian Orelli	Anemic Growth in All the Right Places Amgen's anemia drugs decline, but that's not its future anyway.
The Motley Fool August 31, 2010 Brian Orelli	Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior.
The Motley Fool January 25, 2011 Brian Orelli	2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform.
The Motley Fool February 29, 2008 Brian Lawler	Amgen Playing Hardball There are new developments in the Amgen and Roche patent fight over their anemia drugs.
The Motley Fool July 21, 2008 Brian Lawler	Amgen Rolls the Dice The Food and Drug Administration's impending ruling will determine the drugmaker's near-term fate. Investors, take note.
The Motley Fool August 25, 2008 Brian Lawler	Amgen Gets Its FDA Response Amgen investors can finally breathe a little sigh of relief after the biopharma giant announces that the Food and Drug Administration has finally approved its blood disorder drug.
The Motley Fool December 16, 2003 Rick Aristotle Munarriz	Amgen's Cannibalistic Ways Amgen's prospects look good, and it is planning a large share buyback.
The Motley Fool October 19, 2010 Brian Orelli	When the Status Quo Is a Big Win The lack of an FDA rejection will do just fine. Amgen and Johnson & Johnson seemed to get through the FDA advisory panel process without much problem yesterday.
The Motley Fool July 28, 2008 Brian Lawler	Amgen's Bone-Building Boost The drugmaker gets good news about a top pipeline compound.
The Motley Fool September 28, 2006 Brian Lawler	Amgen Secures Its Future FDA approval for the company's colorectal cancer drug is good news for its future prospects. Investors, take note.
The Motley Fool February 9, 2010 Brian Orelli	Bone Up On This Potential Blockbuster Amgen's denosumab passes another test on its way to potential blockbuster status.
The Motley Fool March 19, 2008 Brian Lawler	Roche to Amgen: We Surrender Roche gives in to a judge's recommendation that it pay a higher royalty to Amgen on sales of its anemia drug Mircera.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool October 24, 2008 Brian Orelli	Amgen's Back Shares of Amgen are up 40% from their lows in March. And for good reason.
BusinessWeek January 14, 2010 Rob Waters	Amgen: Strengthening Bones, Weakening Cancer? Regulators may soon approve an Amgen drug, denosumab, for osteoporosis, but the payoff could be in oncology.
The Motley Fool November 19, 2010 Brian Orelli	One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales.
The Motley Fool February 9, 2011 Luke Timmerman	Amgen Pushes Ahead With "Son of Dmab" for Treating Bones Is there more to Amgen than "Dmab"?
The Motley Fool August 26, 2009 Brian Orelli	Amgen Falls Back on the Future Instead of the TREAT trial for Aranesp, Amgen's new cherry is Prolia's potential to treat cancer patients, for which Amgen could get marketing approval next year.
The Motley Fool January 23, 2004 Alyce Lomax	Amgen's Engine Is the drug company geared up for success?
The Motley Fool April 24, 2007 Ryan Fuhrmann	Red and White Results at Amgen At current levels, this biotech titan could be worth a further look from investors.
The Motley Fool October 20, 2005 Brian Gorman	Amgen's Drive to Diversify The drugmaker pulled in impressive results with its current portfolio, but a drug in late-stage testing could make the company even more attractive to investors.
The Motley Fool March 17, 2008 Brian Lawler	The Panelling on Amgen's Walls One FDA panel ruling is a win, another is much less upsetting than investors feared.